
SUMMARY

In one aspect of the present disclosure, there is provided a use of a compound having the following structure:



or a pharmaceutically acceptable salt thereof

in the manufacture of a medicament for treating a cancer selected from B-prolymphocytic leukemia, non-Hodgkin's lymphoma, diffuse large B cell lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, and cancer of the esophagus in a subject


The present disclosure is directed to a method for treating a cancer in a subject in need of such treatment. In one example, the cancer is selected from acute myeloid leukemia, multiple myeloma, B-prolymphocytic leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, follicular lymphoma, diffuse large B cell lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, lung cancer, breast cancer, triple negative breast cancer, melanoma, glioblastoma, prostate cancer, colon cancer, pancreatic cancer, bone cancer, cancer of the head or neck, skin cancer, cutaneous or intraocular malignant endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, solid tumors of childhood, lymphocytic lymphoma cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma,

environmentally induced cancer, and a PTEN mutant cancer. In another example, the cancer is selected from acute myeloid leukemia, multiple myeloma, B-prolymphocytic leukemia, non-Hodgkin's lymphoma, diffuse large B cell lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, triple negative breast cancer, melanoma, prostate cancer, and cancer of the esophagus. The method comprises the step of administering to the subject one or more times a therapeutically effective amount of at least one compound according to formula (I):

CLAIMS

WHAT IS CLAIMED IS:

1. Use of a compound having the following structure:



or a pharmaceutically acceptable salt thereof
in the manufacture of a medicament for treating a cancer selected from B-prolymphocytic leukemia, non-Hodgkin's lymphoma, diffuse large B cell lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, and cancer of the esophagus in a subject.

2. The use according to claim 1, wherein the cancer is B-prolymphocytic leukemia.

3. The use according to claim 1, wherein the cancer is non-Hodgkin's lymphoma.

4. The use according to claim 1, wherein the cancer is diffuse large B cell lymphoma.

5. The use according to claim 1, wherein the cancer is anaplastic large cell lymphoma.

6. The use according to claim 1, wherein the cancer is mantle cell lymphoma.

7. The use according to claim 1, wherein the cancer is cancer of the esophagus.